Our Mission

Cancer metastasis is resistant to current therapies and responsible for more than 90% of cancer-related deaths. Our primary mission is to determine unknown mechanisms of cancer metastasis from the view of bio-physics to prevent metastasis.

Interactions of metastasized cancer cells and the microenvironment in various metastatic organs can create complexed tumor heterogeneities. These tumor heterogeneities can constitute a major source of therapeutic resistance. Our second mission is to understand the driving forces behind these tumor heterogeneities to improve therapeutic efficacy.

The SATB2-associated syndrome is recently identified very rare genetic disease in children to cause neurological disorders. Our third mission is to identify molecular mechanisms of the consequences of the genetic mutations in neurons to develop potential gene therapy.

Assistant Professor in Nanomedicine, Academic Institute
Assistant Member, Research Institute
Houston Methodist

Dr. Yokoi received his M.D. degree in 1992 and Ph.D. degree in 1997 from the Kanazawa University, School of Medicine and Graduate School of Medicine respectively. Dr. Yokoi completed his postgraduate research fellowship at the University of Texas MD Anderson Cancer Center in Houston, TX. He then accepted a position as an instructor in the Department of Cancer Biology at MD Anderson and as an instructor of general and cardiothoracic surgery for Kanazawa University Hospital in Japan.

He was appointed to the position of assistant professor in the department of cancer biology at MD Anderson in 2007 and then as an assistant member in the department of nanomedicine in The Methodist Hospital Research Institute in 2011. Dr. Yokoi has also held the position of visiting scientist in the department of cancer biology at MD Anderson since 2011 and guest researcher for the Cancer Research Institute of Kanazawa University since 2008-present.

Research Outputs